Sumary of International collaboration secures €1M grant to investigate new treatment target for lymphoma:
- An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center (MSK), New York and Dana-Farber Cancer Institute, Boston has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.
- The aim of the project is to determine how targeting a protein called KDM5 kills lymphoma cells, and to identify the patient groups most likely to benefit from this type of treatment.
- Lymphoma is a type of blood cancer that arises from white blood cells called lymphocytes.
- Changes in the genetic code (mutations) of lymphocytes can cause them to grow uncontrollably and, as a result, these white blood cells collect in lymph nodes and other tissues, eventually giving rise to lymphoma.
- There are two main types of lymphoma: Hodgkin’s and non-Hodgkin’s lymphoma (NHL), which comprise over 60 subtypes.
- Combatting the effects of common lymphoma mutations Research has shown that many lymphoma patients have one or more mutations in a gene called KMT2D.
- The KMT2D gene codes for a protein involved in controlling gene expression within cells;
- however, mutations that stop KMT2D from functioning correctly (leading to changes in the expression of genes required for normal cell function) are the most common mutations detected in lymphoma.